Syros Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for cancer and immune-mediated diseases through gene control. The company's approach focuses on controlling gene expression rather than targeting gene products, utilizing proprietary platforms to identify and drug novel targets. Syros's lead programs include treatments for various blood cancers and solid tumors.
Founded in 2011 and headquartered in Cambridge, Massachusetts, Syros went public on NASDAQ in 2016. The company emerged from pioneering research on super-enhancers and transcriptional control conducted at Harvard and other leading institutions. Syros has advanced multiple candidates through clinical trials, including tamibarotene for acute myeloid leukemia and SY-2101 for solid tumors. The company represents a novel approach in oncology drug development, focusing on the fundamental mechanisms of gene regulation to create more precise and effective therapies.
Syros Pharmaceuticals has received investment from 1 venture capital firm.
Clinical-stage biotech developing cancer treatments by controlling gene expression using proprietary gene control platforms.
Syros Pharmaceuticals has received investment from Third Rock Ventures. These venture capital firms and investors provide both capital and strategic support.
Syros Pharmaceuticals operates in the Biotech sector. Clinical-stage biotech developing cancer treatments by controlling gene expression using proprietary gene control platforms.
